Efficacy and possible side effects of Eltrombopag (Revlan)

Eltrombopag (Eltrombopag) is an oral small-molecule thrombopoietin receptor agonist (TPO-RA). It mainly promotes the proliferation and differentiation of bone marrow megakaryocytes by selectively acting on the thrombopoietin receptor (c-Mpl), thereby increasing the number of platelets. The drug is widely used to treat thrombocytopenia due to various causes, including chronic immune thrombocytopenic purpura (ITP), liver disease-related thrombocytopenia, and platelet decline due to chemotherapy or myelosuppression. Eltrombopag provides patients with a non-invasive oral treatment option that is more convenient for long-term maintenance treatment and improved quality of life than traditional platelet transfusion or glucocorticoid treatment.

Eltrombopag significantly increases platelet counts in patients with chronic immune thrombocytopenic purpura (ITP). Clinical studies have shown that long-term use of eltrombopag can make platelets reach ≥50×10^9/L in about 70%-80% of patients and maintain stability, effectively reducing the risk of bleeding. Eltrombopag offers a new treatment option and can be used as long-term maintenance therapy for patients who cannot tolerate or respond to conventional treatments. In patients with thrombocytopenia associated with liver disease, especially before invasive surgery or liver transplantation, the use of eltrombopag is effective in improving platelet levels, thereby reducing transfusion requirements and surgical risks.

Although eltrombopag is highly effective, certain side effects may occur during its use. The most common adverse reactions include headache, fatigue, nausea, diarrhea, upper abdominal discomfort and musculoskeletal pain, etc. Most of them are mild to moderate and can usually be alleviated through symptomatic treatment or dose adjustment. Some patients may develop hematological abnormalities, such as a decrease in neutrophils or an excessive increase in platelets, during long-term medication. Regular blood routine monitoring and dose adjustment are required to prevent thrombosis. In addition, eltrombopag may have a certain impact on liver function, especially patients with liver disease or individuals with abnormal liver function. Liver function indicators need to be monitored regularly to detect abnormalities in a timely manner and take corresponding intervention measures.

In terms of long-term safety, eltrombopag is generally well tolerated, but potential risks still need to be noted. Rare but serious side effects include thrombotic events (such as deep vein thrombosis, pulmonary embolism) and myelofibrosis. For patients with a high risk of thrombosis or a history of thrombosis, the use of eltrombopag requires strict risk assessment and close monitoring of relevant indicators. In addition, the drug may interact with other drugs. For example, taking it with foods containing calcium or iron may affect absorption. Therefore, it is recommended to take it on an empty stomach or at intervals with specified meals as directed by your doctor.

Overall, eltrombopag exerts a significant platelet-raising effect by targeting the thrombopoietin receptor, providing an effective oral treatment option for patients with thrombocytopenia due to various causes. Although most of its side effects are mild to moderate and controllable, long-term use still requires monitoring of hematology, liver function and potential thrombosis risks under the guidance of a doctor. Combined with individualized dose adjustment and standardized follow-up, eltrombopag can significantly improve patients' platelet levels and quality of life while ensuring safety, and provide a sustained and controllable treatment plan for patients with thrombocytopenia.

Reference materials:https://www.drugs.com/